{"schema_version":"secwatch.filing_event.v1","accession":"0001711279-26-000008","form_type":"8-K","ticker":"KRYS","cik":"0001711279","company_name":"Krystal Biotech, Inc.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.971133+00:00","generated_at":"2026-05-16T10:54:04.029300+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Krystal Biotech pre-announces 2025 VYJUVEK revenue ~$388-389M; outlines 4 product launches by 2030","bullets":["Preliminary Q4 2025 VYJUVEK net revenue $106-107M; full year $388-389M.","Cash, equivalents and investments ~$955M as of Dec 31, 2025.","Targets 4 marketed rare-disease medicines (incl. VYJUVEK) by end of 2030, treating >10,000 patients.","2026 combined non-GAAP R&D and SG&A expense guidance $175-195M (excl. stock comp).","Pipeline milestones: Phase 3 data for KB803 (ocular DEB) and KB801 (NK) in 2026; KB407 CF study enrollment starts."],"urls":{"canonical":"https://secwatch.observer/filing/0001711279-26-000008","json":"https://secwatch.observer/filing/0001711279-26-000008.json","markdown":"https://secwatch.observer/filing/0001711279-26-000008.md","text":"https://secwatch.observer/filing/0001711279-26-000008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711279/000171127926000008/0001711279-26-000008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711279/000171127926000008/krys-20260111.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:54:04.029300+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}